Cell Care Therapeutics, Inc., a Monrovia, CA-based biotechnology company whose mission is to advance stem-cell derived therapies in ophthalmology, closed a $4.3m seed funding round.
Backers included a syndicate of individual investors.
The company intends to use the funds to develop its manufacturing platform and to advance its lead preclinical-stage drug candidate for major eye diseases, including diabetic retinopathy (DR) and neovascular age-related macular degeneration (wet AMD), two of the leading causes of vision loss and blindness in the developed world.
Led by Nicolas Sohl, President and Chief Executive Officer, Cell Care is advancing an regenerative immunotherapy—a new therapeutic approach that has the potential to modulate the immune response in a way that leads to reduced inflammation, permits recovery, and promotes tissue remodeling.
This therapy is derived from components that mesenchymal stem cells secrete, also known as their “secretome.” The secretome contains anti-inflammatory and pro-regenerative molecules that are anticipated to reverse and resolve inflammatory processes while stimulating tissue regeneration.
The technology will allow for the treatment of many degenerative diseases to reduce inflammation, permit recovery, and promote regeneration.